Enanta Pharmaceuticals, Inc.
ENTAAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 23, 2026 | H.C. Wainwright | Brandon Folkes | $20.00(+50%) | $13.37 | StreetInsider |
| Oct 1, 2025 | Jefferies | Akash Tewari | $20.00(+84%) | $10.88 | TheFly |
| Jun 3, 2025 | JMP Securities | Roy Buchanan | $24.00(+234%) | $7.19 | TheFly |
| Dec 9, 2022 | H.C. Wainwright | $56.00(+33%) | $41.96 | Benzinga | |
| Nov 22, 2022 | RBC Capital | $54.00(+16%) | $46.40 | Benzinga | |
| Jul 29, 2022 | Piper Sandler | Yasmeen Rahimi | $87.00(+70%) | $51.27 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| HC Wainwright & Co. | maintain | Buy | Sep 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jun 23, 2026 |
| HC Wainwright & Co. | maintain | Buy | Feb 10, 2026 |
| HC Wainwright & Co. | maintain | Buy | Jan 9, 2026 |
| Jefferies | upgrade | Hold →Buy | Oct 1, 2025 |
| WestPark Capital | maintain | Buy | Sep 30, 2025 |
| Evercore ISI Group | maintain | Outperform | Sep 15, 2025 |
| JMP Securities | maintain | Market Outperform | Aug 12, 2025 |
| JMP Securities | maintain | Market Outperform | Jun 3, 2025 |
| JMP Securities | maintain | Market Outperform | May 14, 2025 |
| HC Wainwright & Co. | maintain | Buy | Feb 11, 2025 |
| JMP Securities | maintain | Market Outperform | Feb 11, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 24, 2024 |
| Baird | maintain | Outperform | Nov 26, 2024 |
| JMP Securities | maintain | Market Outperform | Nov 26, 2024 |
| HC Wainwright & Co. | maintain | Buy | Oct 10, 2024 |
| JMP Securities | maintain | Market Outperform | Oct 9, 2024 |
| JMP Securities | maintain | Market Outperform | Sep 27, 2024 |
| HC Wainwright & Co. | maintain | Buy | Aug 6, 2024 |
| JP Morgan | maintain | Underweight | Aug 6, 2024 |
| HC Wainwright & Co. | maintain | Buy | May 7, 2024 |
| JMP Securities | maintain | Market Outperform | May 7, 2024 |
| JP Morgan | maintain | Underweight | Feb 8, 2024 |
| Oppenheimer | maintain | Perform | Nov 22, 2023 |
| JMP Securities | maintain | Outperform | Nov 21, 2023 |
Earnings History
Next report: Nov 16, 2026 · EPS est. $-0.72| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 10, 2026 | $-0.67 | $-0.51 | $14.4M | $16.8M |
| May 11, 2026 | $-0.45 | $-0.46 | $17.2M | $17.0M |
| Feb 9, 2026 | $-0.42 | $-0.54 | $18.6M | $15.9M |
| Nov 17, 2025 | $-0.87 | $-1.13 | $15.1M | $16.0M |
| Aug 11, 2025 | $-0.85 | $-1.25 | $18.3M | $16.0M |
| May 12, 2025 | $-1.06 | $-1.04 | $14.9M | $16.0M |
| Feb 10, 2025 | $-1.05 | $-1.16 | $17.0M | $17.2M |
| Nov 25, 2024 | $-1.36 | $-1.16 | $67.6M | $17.9M |
News
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences. 2026 Jefferies Global Healthcare Conference in London: Fireside Chat on Wednesday, November 18, 2026, at 2:30 p.m. GMT / 9:30 a.m. EST 9th Annual Evercore Healthcare Conference: Fires.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, announces today that Jay R. Luly, Ph.D., age 70, will retire as President and Chief Executive Officer, by February 1, 2027 following 23 years of leadership with the Company. Dr. Luly will continue to serve as a Strategic Advisor for the remainder of 2027 to support a smooth and orderly tr.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that the first patient has been dosed in RESOLVE, its global Phase 2b/3 clinical trial of zelicapavir in adults at high risk of severe outcomes from RSV infection. Topline data from the Phase 2b portion of the study are expected in 2027. “We are excited to advance our zeli.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that data for zelicapavir, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek™ 2026 being held October 21-24, 2026 virtually and at the Walter E. Washington Convention Center i.
Amphastar Pharmaceuticals (NASDAQ: AMPH - Get Free Report) and Enanta Pharmaceuticals (NASDAQ: ENTA - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, profitability, dividends, analyst recommendations and valuation. Valuation and Earnings This table compares Amphastar
Bank of America Corp DE cut its stake in Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA) by 59.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 26,593 shares of the biotechnology company's stock after selling 39,385 shares during the quarter. Bank of America
[url="]Enanta Pharmaceuticals, Inc.[/url] (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in two investor conferences in September: Baird 2026 Global Healthcare Conference: Fireside Chat on Tuesday, September 15, 2026 at 1:25 p.m. ET H.C. Wainwright 28th Annual Global Investment Conference: Fireside Chat on Wednesday,.
Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.37. This compares to a loss of $0.85 per share a year ago.
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results for its fiscal third quarter ended June 30, 2026. “During the quarter, we continued to build momentum across both our RSV and immunology programs,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta. “Dosing began in LOTUS, our Phase.